[Second report of ofloxacin: clinical study].
We previously reported a study on the antimicrobial action of a chemically synthesized drug, ofloxacin (OFLX) and on its transfer in. This paper describes the results of our clinical study on OFLX. 1. Only small fractions of intra-blood OFLX were transported into female organs such as uterus, ovary and fallopian tube. Our study with the normal delivery method shows that umbilical cord blood concentrations of OFLX is a third to a sixth of maternal blood concentrations and is achieved through trans-placental transfer. Its transfer into amniotic fluid, however, is very low. 2. Forty-one cases, including cases of female intrapelvic inflammation, urinary tract infection, puerperal mastitis, etc., were administered with OFLX at levels of 200 approximately 400 mg/day for 3 approximately 10 days. OFLX were found to be effective in 35 cases. 3. We observed 113 cases to which OFLX was administered, and found only 4 cases of gastrointestinal disturbance and 1 case of suspicion of drug eruption as side effects. Laboratory tests showed no abnormalities due to OFLX in blood, serum biochemical or urine value in the cases examined (26 to 51 cases depending on test).
Seiga
K
K
Iwakuni Hospital.
Syoji
T
T
Tsuchiyama
K
K
Sugiyama
Y
Y
D000328:Adult; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D005312:Fetal Blood / Q000378:metabolism; D005831:Genital Diseases, Female / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D008431:Maternal-Fetal Exchange; D008875:Middle Aged; D015242:Ofloxacin / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy / Q000378:metabolism
D015242:Ofloxacin